SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes.
Schaub JA, AlAkwaa FM, McCown PJ, Naik AS, Nair V, Eddy S, Menon R, Otto EA, Demeke D, Hartman J, Fermin D, O'Connor CL, Subramanian L, Bitzer M, Harned R, Ladd P, Pyle L, Pennathur S, Inoki K, Hodgin JB, Brosius FC 3rd, Nelson RG, Kretzler M, Bjornstad P.
Schaub JA, et al. Among authors: inoki k.
J Clin Invest. 2023 Mar 1;133(5):e164486. doi: 10.1172/JCI164486.
J Clin Invest. 2023.
PMID: 36637914
Free PMC article.